Media and News

PharmaNova, Inc. to Exhibit at the Annual American Association of Pharmaceutical Scientists (AAPS) at 2010 FIP Pharmaceutical Sciences World Congress, New Orleans LA, Morial Convention Center, November 14-18, 2010.

PharmaNova will be exhibiting NovaSperse nanoparticle technology capabilities at the Annual American Association of Pharmaceutical Scientists (AAPS) at 2010 FIP Pharmaceutical Sciences World Congress meeting and exposition at the Ernest N. Morial Convention Center in New Orleans, November 14-18, Booth #2256.   NovaSperse℠ is a unique process developed by PharmaNova for the de novo creation of nanoparticles of tightly controlled particle size.  

AAPS and FIP attracts thousands of business representatives and scientists from pharmaceutical manufacturing and allied support industries, as well as from the FDA and other international regulatory agencies.  The exposition provides an opportunity for PharmaNova to discuss the potential for partnerships and alliances across the globe.  Materials will be provided by PharmaNova at the exhibiting booth.  Stop by our booth and learn more about our exciting new technology base and partnering opportunities.

For additional information on AAPS & FIP 2010 see:  http://www.pswc2010.org/

 

 

About PharmaNova

PharmaNova Inc. is a privately held pharmaceutical company.  Our product candidates are derived from the re‐positioning and enhancement of known drugs using our proprietary NovaSperse℠ nanoparticle technology platform. We address low risk, fast to market products in areas of clear medical need and generate revenue from partnering and licensing strategies with commercialization partners and clients worldwide. PharmaNova also conducts contractual formulation development work applying NovaSperse technology to client‐owned products and compounds to support new product development or the extended life cycle management of existing products.  PharmaNova has new product candidates in various stages in its development pipeline.   Our focus is on the development of novel, improved nanoparticle formulations of ophthalmic, anti-infective and injectable oncology products.



« Back to Media

Member of the media wishing to learn more about Pharmanova should contact:
Rafael Larramendi, President | ral@rochester.rr.com | (585) 919 -9649.